Perceptive Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Perceptive Advisors’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.26M	Buy	+80,956	New	+$1.74M	0.06%	81
2023 Q3	–	Sell	-812,037	Closed	-$35.7M	–	98
2023 Q2	$74M	Buy	812,037 +256,693	+46%	+$22.1M	2.14%	14
2023 Q1	$36.6M	Buy	+555,344	New	+$32M	1.08%	28
2022 Q4	–	Sell	-366,400	Closed	-$25M	–	98
2022 Q3	$25M	Buy	366,400 +45,100	+14%	+$2.67M	0.73%	38
2022 Q2	$14.5M	Sell	321,300 -1,160,400	-78%	-$52.9M	0.46%	50
2022 Q1	$75.3M	Buy	1,481,700 +30,000	+2%	+$1.32M	1.51%	18
2021 Q4	$68.6M	Buy	1,451,700 +836,700	+136%	+$32.9M	1.06%	25
2021 Q3	$20.3M	Sell	615,000 -46,162	-7%	-$2.59M	0.29%	68
2021 Q2	$41.8M	Buy	+661,162	New	+$34.1M	0.54%	47
2020 Q3	–	Sell	-11,418	Closed	-$373K	–	130
2020 Q2	$373K	Hold	11,418	–	–	0.01%	123
2020 Q1	$327K	Buy	+11,418	New	+$405K	0.01%	106

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Perceptive Advisors's APLS Position: Q1 2026 in Review

Perceptive Advisors opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 80,956 shares worth $3.26M. The stake represents 0.06% of the portfolio and ranks #81 among its holdings. This is a return to the name: Perceptive Advisors previously reported a position in APLS as recently as Q2 2023.

Perceptive Advisors first reported a position in APLS in Q1 2020 and has held it in 11 quarters since. The position peaked at $75.3M in Q1 2022. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Perceptive Advisors held 80,956 shares of Apellis Pharmaceuticals worth $3.26M as of Q1 2026.
Apellis Pharmaceuticals was a new Perceptive Advisors position in Q1 2026.
Apellis Pharmaceuticals made up 0.06% of Perceptive Advisors's portfolio in Q1 2026, its #81 holding.
Perceptive Advisors first reported a position in Apellis Pharmaceuticals in Q1 2020 and has held it in 11 quarters since.
Perceptive Advisors's Apellis Pharmaceuticals position peaked at $75.3M in Q1 2022.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.